Loading
BAT8008 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
ASCO 2025 abstract 3024 reports 170 enrolled patients at the January 15, 2025 cutoff, including 147 at the selected 2.4 mg/kg dose. Among efficacy-evaluable patients at that dose, cervical cancer ORR was 36.4% (22 patients) and esophageal cancer ORR 23.1% (13 patients). Two of six patients at 2.7 mg/kg had dose-limiting toxicity. Stomatitis and cytopenias included grade 3 or higher events. These selected nonrandomized cohorts do not establish breast-cancer efficacy.
TROP2-directed monoclonal antibody-drug conjugate delivering exatecan. Connects to TROP2.
1.BAT8008's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BAT8008" OR ABSTRACT:"BAT8008") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BAT8008, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/